ºÚÁϸ£ÀûÉç

Michael T. Andriole

President, Chief Executive Officer, and Director

Mike Andriole joined ºÚÁϸ£ÀûÉç in 2025 as President, Chief Executive Officer, and Director following a career in the biopharmaceutical industry which spans ~25 years.  His career follows a consistent theme of focused execution in clinical development, corporate development and corporate strategy with a particular focus on first-in-class oncology therapies in areas of very high unmet need where no approved treatment exists.

Prior to joining ºÚÁϸ£ÀûÉç, Mike served as President, CEO, and Director of Chimerix, Inc. where, prior to its $935 million all-cash acquisition in April 2025, the Company led development of dordaviprone (Modeyso®), a first-in-class small molecule imipridone approved on August 6, 2025, as the first treatment for recurrent H3 K27M-mutant diffuse midline glioma, a type of malignant brain tumor in children and young adults. Previously, he was Chief Financial Officer and head of corporate development at Endocyte, Inc., where he led a series of strategic transactions that culminated in a $2.1 billion all-cash acquisition by Novartis driven by the late-phase development of its first-in-class targeted radioligand therapy, Lu¹⁷⁷-PSMA-617, which later became the first product approved specifically for PSMA-positive metastatic castration resistant prostate cancer (Pluvicto®). Earlier in his career, Mike spent 16 years at Eli Lilly and Company in various financial, marketing, and global business development roles.

Mike holds a BSBA from Xavier University’s Williams College of Business and an MBA from Indiana University’s Kelley School of Business.

Christine Silverstein

Chief Financial Officer

Christine Silverstein has served as Chief Financial Officer at ºÚÁϸ£ÀûÉç since 2024, bringing more than two decades of expertise in corporate strategy, capital markets, business development, governance and financial planning across both public and private biotechnology companies.

Christine has led the strategy behind securing over $1 billion in capital through a broad range of transactions—including equity financings, partnerships, and M&A. Most recently, she led the successful sale of Emendo Biotherapeutics to Japanese biopharmaceutical company Anges Inc., a cross-border transaction that showcased her ability to drive strategic outcomes and deliver shareholder value.

Prior to joining ºÚÁϸ£ÀûÉç, Christine served as CFO at Excision Biotherapeutics Inc., Emendo Biotherapeutics and Abeona Therapeutics (NASDAQ: ABEO). Her previous leadership roles include Managing Director at SCO Capital Partners, a New York-based biotechnology venture fund. She currently serves on the Boards of Marinus Pharmaceuticals and Abeona Therapeutics, both focused on rare diseases. Christine holds a BSc from the Peter J. Tobin College of Business at St. John’s University and has earned accreditations from the Financial Industry Regulatory Authority (FINRA) and Harvard University.

Graeme Smith

Chief Scientific Officer

Graeme has served as Chief Scientific Officer at ºÚÁϸ£ÀûÉç since 2017.

He has more than 30 years of experience in oncology research, with significant expertise and in-depth knowledge in the field of DNA Damage Response (DDR). He joined ºÚÁϸ£ÀûÉç from AstraZeneca, where he held the position of Senior Director of Bioscience within the Oncology Innovative Medicines and Early Development (IMED) division. In this role, Graeme was a member of the Oncology Research Board and led teams in the discovery and development of novel targeted anti-cancer agents. Prior to that, he was Head and Research Director at KuDOS Pharmaceuticals where he played a key role in the discovery and development of Lynparzaâ„¢ (olaparib), the first targeted DDR inhibitor to reach the market.

Graeme holds a PhD from the University of Edinburgh and subsequently worked as a Research Fellow at the Wellcome/CRC Institute at the University of Cambridge in the laboratory of Professor Sir Steve Jackson, FRS.

Ian Smith

Chief Medical Officer

Ian has served as Chief Medical Officer at ºÚÁϸ£ÀûÉç since 2019.

He has a wealth of experience in the translational research and clinical development of medicines to treat cancer. Prior to joining ºÚÁϸ£ÀûÉç, Ian served as Global Senior Medical Director within Eli Lilly where he led the worldwide clinical development, regulatory approval and subsequent commercialization of key successful breakthrough medicines for multiple indications. Before that, Ian held the position of Medical Science Director of Global Oncology Medicine Development at AstraZeneca, where he led both early and late phase clinical development of several novel cancer therapeutics for both adult and paediatric indications. Prior to joining the pharmaceutical industry, Ian was a Clinical Lecturer at the University of Aberdeen where he led research projects evaluating novel methods of predicting and assessing early treatment response of cancer therapeutics. Ian has served as a reviewer for several oncology journals and sat on national grant awarding panels within the United States and the United Kingdom.

Ian holds a medical degree from the University of Aberdeen.

Roy Ware

Chief Manufacturing and Technology Officer

Roy has served as Chief Manufacturing and Technology Officer since 2026.

He brings more than 25 years of end‑to‑end biopharmaceutical R&D leadership, spanning early discovery through NDA submission, approval, and commercial launch. His career has been defined by building high‑performance teams, driving late‑stage development programs, and delivering regulatory and operational success across multiple therapeutic areas—most notably in oncology.

Before joining ºÚÁϸ£ÀûÉç, Roy served as Chief Manufacturing and Technology Officer at Chimerix, Inc., where he built and led execution‑focused CMC and Supply Chain organizations. Under his leadership, these teams delivered two successful NDAs for Tembexa® (June 2021) and an NDA for Modeyso® (August 2025). He also spearheaded several late‑stage CMC programs supporting global Phase 3 trials in antiviral and oncology indications, including a recent effort in H3 K27M glioma—an area where precision, speed, and scientific rigor are essential.

Earlier in his career, Roy held roles at PharmaCore, Inc. and Scynexis, Inc. (both later acquired by Cambrex), where he advanced chemical process development and cGMP manufacturing for diverse small‑molecule portfolios, including multiple anti‑cancer agents. At Serenex, Inc. (acquired by Pfizer), he led medicinal chemistry programs in oncology (PI3‑kinase inhibitors) and malaria. Roy began his scientific career as a postdoctoral researcher at RTI International, focusing on drug addiction therapies under the mentorship of Dr. F. Ivy Carroll.

Roy earned his PhD from Wake Forest University, an MBA from the Kenan‑Flagler Business School at the University of North Carolina at Chapel Hill, and a BA from the University of North Carolina at Greensboro.

John Graham

VP of CMC

John has served as Vice President of Chemistry, Manufacturing & Controls (CMC) since 2022.

In his role, John is responsible for API & Drug Product development and production through to clinical trial supplies and CMC regulatory interactions. Prior to working at ºÚÁϸ£ÀûÉç, John served as the Vice President of CMC and Technical Operations at Destiny Pharma. Before this, he was the Director of CMC and Pharmaceutical Development at PAION UK Limited. In his 20 years in the biotech field, John has also held different pharmaceutical development roles within several companies in Pharma (Fisons, Astra Charnwood), CDMO (Quintiles) and Biotech (CeNeS Ltd and MISSION Therapeutics). In these roles, he has developed a number of new products within different therapeutic areas including injectables, oral and topical products in support of early to late-stage clinical research, some of which are now commercialized.

Johns holds a BSc degree in Pharmacy and an MSc in Pharmaceutical Analysis from the University of Strathclyde, Glasgow.

Bryony Harrop

VP of Clinical Science

Bryony is Vice President of Clinical Science. She previously served as Vice President of Clinical Development from 2020 to 2025.

Bryony is a seasoned pharmaceutical industry professional with over 20 years of experience through all stages of drug development in cutting-edge oncology clinical trials across a broad range of malignancies. She was previously Oncology Delivery Director at AstraZeneca, where she held various leadership positions in the Early Clinical Development, Global Project Management, and Global Medical Affairs units over a period of fifteen years. Before AstraZeneca, Bryony worked at Eisai and at contract research organizations such as MDS Harris and Chiltern International Limited, and in the NHS at Northampton Community Healthcare Trust.

Bryony holds a BSc in Biochemistry and Biological Chemistry from the University of Nottingham.

Caryn Barnett

VP of Clinical Operations

Caryn has served as Vice President of Clinical Operations since 2026.

Caryn has over 30 years in the biopharmaceutical industry spanning roles in Clinical Operations, Project Management, Late Phase Development (including Regulatory Submissions and Inspections), Early Phase Development, Quality, and Six Sigma.

While her therapeutic area experience is broad, during the last 16 years Caryn’s career has focused in late-phase oncology (solid tumor) drug development having led inspection readiness with subsequent approvals for Cyramza (CRC, NSCLC, gastric cancers), Verzenio (HER2- breast cancer), Pluvicto (PSMA+ metastatic prostate cancer) and Modeyso (H3 K27M-mutant diffuse midline glioma). Caryn spent over 22 years with Eli Lilly and Company and, since 2018, has been with two market-leading biotech companies, Endocyte and Chimerix. In both biotech companies, Caryn led the Clinical Operations team in the successful planning and execution of registration clinical trials followed by US FDA submissions and successful inspection outcomes. In both instances, her work led to FDA approvals for first-in-class agents and in populations that previously had no specific drug approval.

She provided leadership through the smooth transition of her team following the acquisition of each company. Caryn is known for building high performance teams, focused execution, and establishing collaborative relationships both internally and with key external partners.

Desiree Headley

Head of Clinical Science

Desiree is Head of Clinical Science and has served as Vice President of Clinical Science since joining ºÚÁϸ£ÀûÉç in 2021.

Desiree has over 20 years of pharmaceutical experience working in various functions across oncology research & development in a wide range of cancer indications. Most recently, she worked at GSK as a Cell and Gene Therapy Specialist overseeing investigator engagement initiatives and study oversight for multiple phase I/II trials. Prior to that, Desiree worked at AstraZeneca and Eli Lilly as a medical scientist responsible for the medical oversight and conduct of small and large phase II and III clinical trials. Desiree’s vast experience in late-stage oncology clinical development also includes regulatory submissions and approvals and working with product launch and commercialization teams.

Desiree has a BSc in Health Science from Eastern University and an MSc in Clinical Research from George Washington University.

Robert Heald

VP of Chemistry

Robert has served as Vice President of Chemistry since 2016.

Rob is a seasoned medicinal chemist and drug discovery expert with over 20 years of industrial experience. Before joining ºÚÁϸ£ÀûÉç, Rob was the Head of Chemistry at Akesios Therapeutics. Prior to this, Rob served as the Director of Chemistry at Argenta Discovery (latterly Charles River) where he managed a group of over 30 chemists and led teams and projects in collaboration with a wide range of institutions, from universities to large biotech and Pharma. These collaborations included 10 years with Genentech and 5 years with Chiesi. During this time, his teams were responsible for the discovery of 6 clinical candidates for oncology and respiratory indications, the most advanced of which is now in Phase III clinical studies. Rob is also an author or inventor of over 50 publications and patents.

Rob holds a BSc in Chemistry and a PhD in Anti-Cancer Drug Design and Synthesis from the University of Nottingham

Gillian Langford

VP of Translational Science

Gillian has served as Vice President of Translational Science since 2019.

Gillian has over 25 years of research and development experience in both pharmaceutical and biotechnology companies. Before ºÚÁϸ£ÀûÉç, Gillian was at Bicycle Therapeutics where she was part of the leadership team and was VP of Clinical and Project Management responsible for moving Bicycle’s lead compound into the clinic. Prior to this, she was Director of Programme Management at Boyd Consultants and worked with European and North American companies developing oncology products and gene-based medicines. Gillian also worked at Alizyme Therapeutics, Ark Therapeutics and Imutran Ltd, a Novartis Pharma AG company. At Ark Therapeutics, Gillian was responsible for all aspects of the company’s lead gene therapy product, including non-clinical studies, manufacturing, regulatory and clinical trials (phases II and III). At Imutran Gillian was Unit Head of Molecular Biology and subsequently as Unit Head of Retroviral research managing internal research projects and collaborations with academic groups.

Gillian graduated from Imperial College London and obtained her PhD in Molecular Biology at York University.

Helen Robinson

VP of Biology

Helen has served as Vice President of Biology since 2017.

Helen has 20 years of experience in oncology research, the majority within the DNA Damage Response (DDR) field. Since joining ºÚÁϸ£ÀûÉç, she has overseen the building of the DDR biology platform and continues to lead the biology department, supporting the drug discovery process from target ID and cell assay development through to identifying and validating patient selection hypotheses. Prior to ºÚÁϸ£ÀûÉç, Helen was at MISSION Therapeutics where she was both a team and project leader responsible for various drug discovery efforts up to the preclinical stage, leading both biomarker discovery and new targets functional teams. Before this, Helen was a Research Associate at the University of Cambridge and a Senior Scientist at KuDOS Pharmaceuticals.

Helen holds a PhD in Cancer Sciences from the University of Glasgow and a BSc in Biochemistry with Molecular Biology from the University of Leeds.

Michael T. Andriole

President, Chief Executive Officer, and Director

Mike Andriole joined ºÚÁϸ£ÀûÉç in 2025 as President, Chief Executive Officer, and Director following a career in the biopharmaceutical industry which spans ~25 years.  His career follows a consistent theme of focused execution in clinical development, corporate development and corporate strategy with a particular focus on first-in-class oncology therapies in areas of very high unmet need where no approved treatment exists.

Prior to joining ºÚÁϸ£ÀûÉç, Mike served as President, CEO, and Director of Chimerix, Inc. where, prior to its $935 million all-cash acquisition in April 2025, the Company led development of dordaviprone (Modeyso®), a first-in-class small molecule imipridone approved on August 6, 2025, as the first treatment for recurrent H3 K27M-mutant diffuse midline glioma, a type of malignant brain tumor in children and young adults. Previously, he was Chief Financial Officer and head of corporate development at Endocyte, Inc., where he led a series of strategic transactions that culminated in a $2.1 billion all-cash acquisition by Novartis driven by the late-phase development of its first-in-class targeted radioligand therapy, Lu¹⁷⁷-PSMA-617, which later became the first product approved specifically for PSMA-positive metastatic castration resistant prostate cancer (Pluvicto®). Earlier in his career, Mike spent 16 years at Eli Lilly and Company in various financial, marketing, and global business development roles.

Mike holds a BSBA from Xavier University’s Williams College of Business and an MBA from Indiana University’s Kelley School of Business.

Samantha Truex

Board Chair

Samantha Truex currently serves as Chair of the ºÚÁϸ£ÀûÉç Board. She is the CEO of Oblenio Bio and CEO-in-residence at Aditum Bio. Samantha was the founding CEO of Upstream Bio and has served in leadership roles at multiple venture-backed companies, including as CEO of Quench Bio, COO of Synlogic, and CBO for Padlock Therapeutics. Previously, she was Vice President of Corporate Development at Biogen where she led transactional business development activities and served as program executive for now-marketed products FAMPYRA,® ELOCTATEâ„¢ and ALPROLIXâ„¢. Sam also previously worked in Corporate Development at Genzyme, Chiron Diagnostics and Health Advances.

In addition to serving on the board of ºÚÁϸ£ÀûÉç, she serves on the board of Avalo Therapeutics (NASDAQ: AVTX) and has previously served on the boards of Hotspot Therapeutics, iPierian (acquired by Bristol Myers Squibb) and True North (acquired by Bioverativ Inc.).

Samantha earned a BA in biology from Dartmouth College, a BE in biomedical engineering from the Thayer School at Dartmouth and an MBA from the Tuck School at Dartmouth.

Irena Melnikova

Director

Irena Melnikova, is a Partner at Pfizer Ventures and serves as a board director of Priovant Therapeutics, Crossbow Therapeutics, Flare Therapeutics and Telavant Holdings.

Irena is an accomplished biopharma and finance executive with over 20 years of experience in equity financings in both public and private markets, corporate strategy, business development, and operations. Prior to Pfizer Ventures, she served as the Chief Financial Officer at Umoja Biopharma where she was a senior member of the executive team responsible for all aspects of financial strategy and operations of the company. Prior to Umoja, Irena was a Managing Director, Biopharma Investment Banking at SVB Leerink, where she provided critical advice to biopharma companies and their boards on equity financing strategies, completing over 80 transactions raising over $9 billion for clients. Earlier in her career, she held leadership positions at Sanofi and TVM Capital.

Irena received a PhD in Molecular Medicine/Molecular Biology from the University of Texas Health Science Center at San Antonio.

Michelle Doig

Director

Michelle Doig is a Partner and Head of Corporate Development at Omega Funds. She is currently serving as a Director and President of Omega Alpha SPAC.

Michelle has over 20 years of experience working with life sciences companies at leading international venture capital and investment banking firms. Prior to joining Omega, she was Director of Corporate Finance at Third Rock Ventures where she supported numerous portfolio companies. Before this, Michelle was a Principal, Corporate Finance at Abingworth. Michelle began her career as a life sciences investment banker with multiple investment firms, including Morgan Stanley (Toronto and New York), JPM H&Q (New York and San Francisco) and Lehman Brothers (London, UK).

Michelle holds an HBA in Business Administration from the Richard Ivey School of Business at Western University, London, Ontario.

John Hohneker

Director

John Hohneker, M.D., brings over 30 years of extensive experience in drug development and leadership across the biotech and pharmaceutical sectors. He most recently served as President and Chief Executive Officer of Anokion SA. Prior to this, he held the role of President of Research and Development at FORMA Therapeutics Inc. Before joining FORMA Therapeutics, Dr. Hohneker held roles of increasing responsibility at Novartis AG, including most recently as Senior Vice President and Global Head of Development, Immunology, and Dermatology.

Dr. Hohneker currently serves on the Board of Directors of Arrivent Biopharma, Carisma Therapeutics, Curis, Inc., Sonata Therapeutics, Inc., and Trishula Therapeutics, Inc. Dr. Hohneker received his bachelor’s degree in chemistry from Gettysburg College and his M.D. from the Rutgers School of Biomedical and Health Sciences (formerly the University of Medicine and Dentistry of New Jersey-Rutgers Medical School).

René Kuijten

Director

René Kuijten is Head of EQT Life Sciences and Partner at EQT. He is also Vice Chairman of the Supervisory Board of Oncode Institute which he co-founded, and he advises the Dutch government on life sciences policies through HealthHolland.

René was Managing Partner at LSP from 2001 until 2022, when LSP joined forces with EQT and was renamed EQT Life Sciences. Prior to LSP, René was senior consultant for 8 years at McKinsey & Company and co-leader of their European Healthcare Practice. Furthermore, he served on the board of the Dutch Private Equity and Venture Capital Association (NVP) for 12 years.

René obtained his MD from Utrecht University; his PhD from the University of Amsterdam on research performed as a WHO fellow at the University of Pennsylvania. He also obtained an MBA from INSEAD in Fontainebleau.

Nikola Trbovic

Director

Nikola is a Partner at SV Health Investors in the Biotech team.

Previously, Nikola was a Partner at Pfizer Ventures, Pfizer’s corporate venture capital group. There he was responsible for investments in emerging companies developing transformative medicines spanning all therapeutic areas and modalities aligned with the future directions of Pfizer. In prior roles at Pfizer, Nikola held responsibilities for R&D technology investments, R&D strategy and early clinical portfolio management within the R&D organization. Nikola joined Pfizer from McKinsey & Co., where he served as an Associate Principal and senior member of the Pharmaceuticals Practice, advising top pharmaceutical, biotech, and healthcare companies on a range of strategy, corporate finance and commercial topics across geographies and therapeutic areas.

Nikola has a PhD in Biochemistry and Molecular Biophysics from Columbia University and a Diploma in Biochemistry from Goethe University Frankfurt.